--- a
+++ b/clusters/3009knumclusters/clust_236.txt
@@ -0,0 +1,415 @@
+No history of atrial fibrillation or myocardial infarction
+Patients with a history of the following within =< 12 months of study entry are not eligible:\r\n* Arterial thromboembolic events\r\n* Unstable angina\r\n* Myocardial Infarction
+No angina or myocardial infarction within 182 days of registration; in view of potential cardiac risk with lenalidomide, patients with stable angina will be excluded
+No clinically significant cardiac arrhythmias, stroke or myocardial infarction within 6 months prior to enrollment
+Myocardial infarction within the past 6 months
+Patients must not have a myocardial infarction within 6 months prior to registration
+History of myocardial infarction or unstable angina within 12 months prior to day 1
+Patients with myocardial infarction or unstable angina < 6 months prior to starting study drug
+History of myocardial infarction within 6 months.
+Unstable angina or myocardial infarction.
+History of myocardial infarction, unstable angina, cardiac or other vascular stenting, angioplasty, or cardiac or vascular surgery within 6 months prior to day 1 of study treatment
+Severe arterial thromboembolic events (myocardial infarction, unstable angina pectoris, stroke) less than 6 months before inclusion
+Acute myocardial infarction </=6 months prior to enrollment
+History of acute coronary syndromes, including myocardial infarction, coronary artery bypass graft, unstable angina, coronary angioplasty or stenting within past 24 weeks.
+Patients with a history of known coronary artery disease or a myocardial infarction within 12 months prior to pre-registration
+Must not have a history of myocardial infarction, severe or unstable angina, peripheral vascular disease or familial QT prolongation
+Myocardial infarction of unstable angina within 6 months prior to the planned start date of study drug.
+Myocardial infarction or unstable angina pectoris within 6 months prior to randomization.
+Severe/unstable angina pectoris, or myocardial infarction within 6 months prior to study entry
+Myocardial infarction within 6 months prior to study entry,
+Myocardial infarction within the last 6 months
+Acute myocardial infarction ?6 months prior to Day 1
+Any comorbidity or condition which, in the opinion of the investigator, may interfere with the assessments and procedures of this protocol e.g. unstable angina, myocardial infarction within 6 months, severe infection, etc.
+Myocardial infarction or unstable angina within 6 months of the first date of treatment on this study.
+History of cerebral vascular accident, unstable angina, myocardial infarction, or ventricular arrhythmia within the last 6 months
+Any history of clinically relevant coronary artery disease or myocardial infarction within the last 3 years.
+Myocardial infarction within the previous 6 months before planned first dose of study drug
+Myocardial infarction within 6 months of study dose
+Acute myocardial infarction or angina pectoris.
+12. Subjects with any other concurrent, uncontrolled illness, including known psychiatric or substance abuse disorders which may interfere with the ability of the subject to cooperate and participate in the trial. Other examples of such conditions would include unstable angina, myocardial infarction (MI) or cerebrovascular accident (CVA) within 6 months of study entry.
+Subjects with myocardial infarction (heart attack) within 1 year
+Unstable angina pectoris or myocardial infarction ? 3 months prior to starting treatment in the study.
+History of angina pectoris, symptomatic pericarditis, or myocardial infarction within 12 months prior to study entry;
+No uncontrolled arrhythmia; no myocardial infarction in the last 6 months
+Having known myocardial infarction or unstable angina within 6 months before first ZW25 dosing
+Myocardial infarction within 6 months prior to initiation of screening
+History of myocardial infarction or unstable angina within 6 months of registration
+Other serious intercurrent chronic or acute illness, including myocardial infarction or cerebrovascular event within 6 months
+Any history of myocardial infarction in the past 12 months
+Myocardial infarction and/or new ST elevation
+Ischemic cardiac event including myocardial infarction within 3 months prior to first dose
+Myocardial infarction,
+Myocardial infarction within 6 months prior to screening, or pericardial effusion,
+Have a recent history of myocardial infarction (within the past 2 months)
+Myocardial infarction within 6 months of course 1 day 1 (C1D1); subjects with a history of myocardial infarction between 6 and 12 months prior to C1D1 who are asymptomatic and have had a negative cardiac risk assessment (treadmill stress test, nuclear medicine stress test, or stress echocardiogram) since the event may participate
+ischemic peripheral vascular disease, myocardial infarction within the past 6 months,
+History of myocardial infarction within the last 6 months.
+History of myocardial infarction or unstable angina within 6 months prior to day 1
+History of myocardial infarction, acute coronary syndromes (including unstable angina), coronary angioplasty and/or stent placement within 6 months prior to study drug dosing
+Severe uncontrolled cardiac disease within 6 months of study entry, including but not limited to uncontrolled hypertension; unstable angina; myocardial infarction (MI) or cerebrovascular accident (CVA).
+Myocardial infarction in the previous 12 weeks (from the start of treatment)
+Has a history of myocardial infarction or unstable angina within 6 months before enrollment
+History of myocardial infarction within 6 months of the randomization
+History of myocardial infarction, cardiac angioplasty or stenting, unstable angina, or other clinically significant cardiac disease within 12 months of enrollment
+Significant cardiac disease such as recent myocardial infarction
+Patients with a significant history of cardiovascular disease (e.g., myocardial infarction [MI], thrombotic or thromboembolic event in the last 6 months)
+Patients with unstable angina and/or myocardial infarction within 6 months prior to screening
+Patients within 6 months of myocardial infarction (MI) and stroke will be excluded
+Myocardial infarction (MI) within 6 months of Screening Visit.
+Myocardial infarction within the 6 months prior to study drug administration
+History of myocardial infarction or unstable angina within 6 months prior to first study treatment
+History of a recent myocardial infarction (within one year), a past myocardial infarction (more than one year ago) along with current coronary symptoms requiring medications
+Ischemic myocardial event including angina requiring therapy and artery revascularization procedures, myocardial infarction, and unstable symptomatic ischemic heart disease.
+Has history of myocardial infarction within the past 6 months.
+Myocardial infarction or cerebrovascular accident (CVA) within 6 months.
+Arterial or venous thrombi (including stroke), myocardial infarction, admission for unstable angina, cardiac angioplasty, or stenting.
+Patient has any unstable or uncontrolled medical condition that would make it potentially unsafe to undergo TURBT including a previous stroke or myocardial infarction within 6 months
+Myocardial infarction within 3 months of registration.
+Patients with a history of myocardial infarction within the last 6 months or unstable / uncontrolled angina pectoris or history of severe and/or uncontrolled ventricular arrhythmias
+Patients with arterial thrombotic events, such as cerebrovascular accident or myocardial infarction, within 6 months of enrollment
+Ischemic cardiac event including myocardial infarction within 3 months prior to first dose;
+Significant cardiovascular risk including, but not limited to, recent (within 4 weeks) coronary stenting or myocardial infarction within 6 months
+Myocardial infarction within 6 months of starting study drug
+Evidence of ischemia or myocardial infarction within the past 6 months, or any significant abnormality on ECG.
+History of acute coronary syndromes (including myocardial infarction, unstable angina, coronary artery bypass grafting, coronary angioplasty, or stenting) or symptomatic pericarditis within 6 months prior to registration.
+History of cerebrovascular accident (CVA), myocardial infarction or unstable angina within the previous 6 months before starting therapy.
+Inpatient admission to a hospital for unstable angina or myocardial infarction within the last 6 months prior to first dose or percutaneous cardiac intervention with recent stent within 6 months or coronary artery bypass grafting within 6 months
+Myocardial infarction within 6 months
+History of myocardial infarction within 6 months prior to registration
+History of myocardial infarction (MI), angina pectoris, coronary artery bypass graft (CABG) within 6 months prior to starting study treatment.
+Patients with history of myocardial infarction within 6 months
+No stroke, myocardial infarction, or major surgery within 3 months of starting on therapy
+History of an ischemic cardiac event including myocardial infarction within 3 months of study entry
+Myocardial infarction within 6 months of study entry
+Unstable angina or a history of myocardial ischemia within prior 6 months
+No cerebrovascular accident (CVA) within 6 months, no myocardial infarction (MI) within 6 months
+mCRPC EXPANSION COHORT: Any of the following within 6 months before the first dose of study treatment:\r\n* Unstable angina pectoris\r\n* Stroke (including TIA, or other ischemic event)\r\n* Myocardial infarction
+No evidence of a history of a stroke or myocardial infarction within the last 6 months prior to study enrollment
+No uncontrolled arrhythmia; no myocardial infarction in the last 6 months
+Active ischemic heart disease or history of myocardial infarction within six months.
+Unstable angina pectoris or acute myocardial infarction =< 3 months prior to starting study drug
+History of myocardial infarction or unstable angina within 3 months prior to cycle 1, day 1
+Myocardial infarction or unstable angina within 6 months of enrollment
+Significant cardiovascular risk including, but not limited to, recent (within 4 weeks) coronary stenting or myocardial infarction within 6 months
+Arterial ischemic event (e.g., unstable angina, myocardial infarction, stroke) within 6 months of study entry
+Unstable angina pectoris or acute myocardial infarction =< 3 months prior to starting study drug
+History of myocardial infarction or cerebrovascular accident within 6 months of enrollment date
+Myocardial infarction within 6 months of study entry
+Myocardial infarction less than 6 months before study enrollment
+Myocardial infarction within the past 12 months, or stable or unstable angina
+History of myocardial infarction or severe unstable angina
+Myocardial infarction or cardiac surgery within 6 months prior to enrollment
+myocardial infarction in the previous six months
+Myocardial infarction within 1 year of study entry; subjects with a history of myocardial infarction between 6 and 12 months prior to study entry who are asymptomatic and have had a negative cardiac risk assessment (treadmill stress test, nuclear medicine stress test, or stress echocardiogram) since the event may participate
+Any history of peripheral vascular infarction, including visceral infarction
+Patients with a history of myocardial infarction, unstable angina, or uncontrolled arrhythmia within 3 months from enrollment.
+Myocardial infarction (MI) within 3 months. • Presence of active, uncontrolled infection. • Known central nervous system illness (e.g., Alzheimer's disease).
+Myocardial infarction
+ST elevation myocardial infarction within 30 days prior to enrollment; unstable angina or significant, untreated arrhythmias within 30 days prior to enrollment
+History of myocardial infarction, stroke, ventricular arrhythmia, or symptomatic conduction abnormality within 6 months
+Subjects that have had a myocardial infarction within the last 6 months
+Patients with a history of myocardial infarction that is < 3 months prior to registration
+No cerebrovascular accident (CVA) within 6 months, no recent myocardial infarction (MI) within 6 months
+History of myocardial infarction or unstable angina within 6 months prior to study enrollment
+Patients with a history of myocardial infarction that is < 3 months prior to registration
+Transmural myocardial infarction within the last 6 months
+Patients experiencing a cardiac events (acute coronary syndrome, myocardial infarction, or ischemia) within the 3 months prior to accrual
+History of myocardial infarction or unstable angina within the past 12 months
+History of myocardial infarction or unstable angina within 6 months prior to day 1
+Prior myocardial infarction within one year of study entry
+Subject has a significant history of cardiovascular disease (e.g., myocardial infarction [MI], thrombotic or thromboembolic event in the last 6 months)
+Have active angina pectoris or recent myocardial infarction (within 6 months).
+History of myocardial infarction within 6 months
+Patients with a myocardial infarction or unstable angina within 6 months of study entry
+Myocardial infarction < 6 months prior to screening
+Known history of Torsade de Pointes, unstable cardiac arrhythmia or proarrhythmic conditions, or a history of recent myocardial infarction within 90 days of study entry.
+Patients with a history of myocardial infarction or stroke within the last 6 months
+Unstable angina or a history of myocardial ischemia within prior 6 months
+History of myocardial infarction within 6 months with a residual arrhythmia that in the opinion of the investigator, increases the risk of ventricular arrhythmia
+Patients with clinically significant cardiovascular disease: History of CVA (cerebrovascular accident) within 6 months, myocardial infarction or unstable angina within 6 months, unstable angina pectoris
+History of any one or more of the following cardiovascular conditions within the past 6 months: \r\n* Cardiac angioplasty or stenting \r\n* Myocardial infarction \r\n* Unstable angina \r\n* Coronary artery bypass graft surgery \r\n* Symptomatic peripheral vascular disease
+Patients with clinically significant cardiovascular disease: history of cerebrovascular accident (CVA) within 6 months, myocardial infarction or unstable angina within 6 months, or unstable angina pectoris
+History of cerebral vascular accident (CVA), myocardial infarction or unstable angina within the previous six months before starting therapy
+Documented myocardial infarction within six months of enrollment.
+Myocardial infarction or uncontrolled angina within 6 months
+Myocardial infarction (MI) within 6 months prior to the first dose of study drug;
+Acute myocardial infarction or unstable angina pectoris < 6 months prior to Screening
+History of a stroke, myocardial infarction, or unstable angina in the previous 6 months
+Significant cardiac disease such as recent myocardial infarction
+History of myocardial infarction, unstable angina, cardiac or other vascular stenting, angioplasty, or surgery within 6 months prior to day 1 of study treatment;
+Myocardial infarction (MI) within past 6 months before randomization
+History of myocardial infarction within 6 months of study entry.
+Myocardial infarction within 6 months prior to study entry
+Has a medical history of myocardial infarction or unstable angina
+History of myocardial infarction, acute coronary syndromes or coronary angioplasty/stenting/bypass grafting within the past 6 months.
+Active ischemic heart disease or history of myocardial infarction within six months.
+History of or current coronary artery disease, myocardial infarction, angina pectoris, angioplasty or coronary bypass surgery
+History of myocardial infarction within 6 months or unstable angina within the past 6 months.
+Unstable cardiac disease despite treatment, myocardial infarction within 6 months prior to study entry
+Patients with documented myocardial infarction within six months of protocol entry
+Myocardial infarction (MI) within the last 3 months
+Recent (within twelve months) myocardial infarction.
+History of stroke, unstable angina, myocardial infarction, or ventricular arrhythmia requiring medication or mechanical control within the last 6 months
+Evidence of a history of a stroke or myocardial infarction within the last 6 months prior to study enrollment
+History of cerebrovascular accident, myocardial infarction or unstable angina within the previous 6 months before starting therapy
+Patients with a history of myocardial infarction that is < 3 months prior to registration
+History of acute coronary syndromes (including myocardial infarction and unstable angina), coronary angioplasty, or stenting within 6 months prior to enrollment
+Myocardial infarction within 3 months of study initiation
+History of acute coronary syndromes (including myocardial infarction, unstable angina, coronary artery bypass graft, coronary angioplasty, or stenting) < 6 months prior to screening
+History of myocardial infarction within 6 months of enrollment.
+Myocardial infarction or unstable angina less than 6 months before registration
+History of myocardial infarction
+History of myocardial infarction or unstable angina within 6 months prior to Day 1
+Any active angina or any unstable angina pectoris or myocardial infarction within one year of study entry
+Subjects with a history of myocardial infarction or uncontrolled cardiac dysfunction\n             during the previous 6 months
+Must not have a history of myocardial infarction, severe or unstable angina, or peripheral vascular disease
+Acute myocardial infarction =< 12 months prior to starting drug
+Clinically significant cardiomyopathy or cardiac complications, including recent myocardial infarction or cerebrovascular accident within one year, and/or unstable or uncontrolled angina
+Myocardial infarction or unstable angina < 6 months prior to registration
+Patients with a known history of myocardial infarction or cerebrovascular accident are not eligible
+History of myocardial infarction or unstable angina within 6 months prior to study enrollment
+Subjects with a history of myocardial infarction within the last 6 months of screening.
+Patients with a history of myocardial infarction within the 6 months prior to screening
+Patient must have no history of myocardial infarction, hospital admission for unstable angina, cardiac angioplasty or stenting within 6 months of randomization
+Unstable angina and/or myocardial infarction within 6 months prior to screening
+History of any one or more of the following cardiovascular conditions within the past 6 months:\r\n* Cardiac angioplasty or stenting\r\n* Myocardial infarction\r\n* Unstable angina\r\n* Coronary artery bypass graft surgery\r\n* Symptomatic peripheral arterial vascular disease
+Symptomatic ischemia or myocardial infarction within the previous 6 mo
+History of myocardial infarction (within 12 months) or unstable angina (within 6 months) prior to study enrolment.
+Myocardial infarction
+Myocardial infarction
+Patients who have had a myocardial infarction within 6 months (24 weeks) prior to registration are not eligible
+History of cerebrovascular or myocardial ischemia within 6 months of initiation
+Patients are excluded if they have a history of myocardial infarction or unstable angina within 6 months prior to randomization
+Transmural myocardial infarction within the last 6 months
+myocardial infarction within 6 months prior to randomization;
+No myocardial infarction < 6 months
+Myocardial infarction
+History of thrombotic or hemorrhagic stroke or myocardial infarction within 6 months.
+History of myocardial infarction within 6 months.
+Have active angina pectoris, stroke or recent myocardial infarction (within 6 months).
+Arterial thromboembolic events (myocardial infarction, unstable angina pectoris, stroke) < 6 months prior to enrollment
+Myocardial infarction
+History of stroke, unstable angina, myocardial infarction, or ventricular arrhythmia requiring medication or mechanical control within the last 6 months;
+Acute myocardial infarction or angina pectoris ? 6 months prior to starting study drug
+History of myocardial infarction (MI), angina pectoris, symptomatic pericarditis, or coronary artery bypass graft (CABG) within 6 months prior to study entry
+Transmural myocardial infarction within the last 6 months
+Unstable angina pectoris or myocardial infarction ? 3 months prior to starting CC-122.
+Significant cardiac dysfunction; myocardial infarction within 12 months; unstable, poorly controlled angina pectoris.
+Documented myocardial infarction or unstable/uncontrolled cardiac disease within 6 months of randomization
+Myocardial infarction within the last 3 months
+History of acute coronary syndromes (including myocardial infarction, unstable angina, coronary artery bypass grafting, coronary angioplasty, or stenting) or symptomatic pericarditis within 12 months prior to screening
+Unstable angina (anginal symptoms at rest), new-onset angina within 3 months before randomization, or myocardial infarction within 6 months before randomization.
+Unstable angina or new-onset angina (begun within the last 3 months), or myocardial infarction within the 6 months prior to enrollment
+Transmural myocardial infarction within the last 6 months prior to registration
+Myocardial infarction or unstable angina within 6 months prior to registration.
+History of acute coronary syndromes (including myocardial infarction and angina), coronary angioplasty, or stenting within 6 months prior to enrollment.
+History or evidence of cardiovascular risk including any of the following -- History of acute coronary syndromes (including myocardial infarction and angina), coronary angioplasty, or stenting within 6 months prior to enrollment. Additional Exclusion Criteria for Part E
+Patients who have had a myocardial infarction, intracranial bleed, or stroke within the past 6 months are not eligible
+Diagnosis of unstable angina or myocardial infarction within 6 months of study entry
+Patients with a history of myocardial infarction, unstable angina, or cerebrovascular accident < 6 months prior to registration
+Patients with a history of stroke, myocardial infarction, or unstable angina within 6 months prior to registration are not eligible
+History of myocardial infarction, unstable angina, cardiac or other vascular stenting, angioplasty, or cardiac surgery =< 6 months prior to registration
+History of myocardial infarction, cardiac angioplasty or stenting, unstable angina, or other clinically significant cardiac disease within 12 months of enrollment
+Acute myocardial infarction or unstable angina pectoris < 6 months prior to Screening
+History of myocardial infarction, acute coronary syndromes (including unstable angina), coronary angioplasty, and/or stenting up to 12 weeks before Cycle 1, Day
+History of myocardial infarction, unstable angina, cardiac or other vascular stenting, angioplasty, or surgery =< 12 months prior to randomization
+Subjects with active cardiovascular disease not medically controlled or those who have had myocardial infarction in the past 6 months..
+Myocardial infarction within 6 months before the Day 1 visit.
+The participant has unstable angina pectoris, angioplasty, cardiac stenting, or myocardial infarction within 6 months of randomization.
+Myocardial infarction or unstable angina within 6 months prior to Day 1 of the study.
+History of myocardial infarction within 6 months prior to screening
+Unstable angina (angina symptoms at rest), new-onset angina (begun within the last 3 months) or myocardial infarction less than 6 months prior to randomization
+Myocardial infarction or cerebrovascular accident within 6 months prior to study registration
+Patients with any of the following risk factors should have a baseline cardiac function assessment:\r\n* Prior treatment with anthracyclines\r\n* Prior treatment with trastuzumab\r\n* Prior central thoracic radiation therapy (RT), including RT to the heart\r\n* History of myocardial infarction within 6 to 12 months (patients with history of myocardial infarction within 6 months are excluded from the study\r\n* A NYHA classification of II controlled with treatment\r\n* Prior history of impaired cardiac function
+Myocardial infarction within 6 months of cycle one, day one (C1D1); subjects with a history of myocardial infarction between 6 and 12 months prior to C1D1 who are asymptomatic and have had a negative cardiac risk assessment (treadmill stress test, nuclear medicine stress test, or stress echocardiogram) since the event may participate
+Myocardial infarction within 6 months before C1D1.
+History of cerebrovascular accident (CVA), myocardial infarction or unstable angina within the previous 6 months before starting therapy
+Documented myocardial infarction <6 months from study entry
+History of acute coronary syndromes (specifically, myocardial infarction and unstable angina), severe/unstable angina, coronary angioplasty, or stenting within 6 months prior to the initiation of therapy on this protocol
+Acute myocardial infarction
+Myocardial infarction (MI) within 6 months prior to the first dose of brigatinib
+Subjects with a history of myocardial infarction within the last 6 months.
+Myocardial infarction
+History of stroke, unstable angina, myocardial infarction, or ventricular arrhythmia requiring medication or mechanical control within the last 6 months
+Myocardial infarction within 6 months of registration
+Myocardial infarction or unstable angina within 6 months prior to the first dose of study drug.
+History of angina pectoris, symptomatic pericarditis, or myocardial infarction within 12 months prior to study entry
+Patients within three months of a myocardial infarction
+Myocardial infarction in the previous 12 weeks (from the start of treatment)
+PART B: Any history of myocardial infarction or embolic/occlusive cerebro-vascular accident (stroke)
+Subjects with a history of myocardial infarction within the last 6 months of screening.
+Myocardial infarction in the previous 12 weeks (from the start of treatment)
+History of congestive heart failure or myocardial infarction within the previous six months
+History of stroke, unstable angina, myocardial infarction, or ventricular arrhythmia requiring medication or mechanical control within the last 6 months prior to first dose of study drug
+Patients with a history of myocardial infarction that is < 3 months prior to registration
+History of a myocardial infarction within 6 months
+Patients with a history of the following within =< 12 months of study entry are not eligible:\r\n* Arterial thromboembolic events\r\n* Unstable angina\r\n* Myocardial Infarction
+Patients who have had a myocardial infarction, transient ischemic attack, unstable angina, or cardiovascular symptoms (CVS) within 6 months before treatment
+Myocardial infarction within the past 6 months before the first dose of study drug
+History of myocardial infarction, acute coronary syndromes (including unstable angina), coronary angioplasty and/or coronary artery stenting within the past 6 months
+History of acute coronary syndromes (including myocardial infarction and unstable angina), coronary angioplasty, or stenting within 6 months prior to study enrollment
+History of myocardial infarction or unstable angina within 6 months prior to study Day
+History or clinical signs of myocardial infarction within 1 year prior to study entry
+History of myocardial infarction within 12 months prior to day 1 or clinically significant coronary disease
+None of the following conditions within 6 months prior to enrollment: myocardial infarction, stroke or symptomatic peripheral vascular disease
+None of the following conditions within 6 months prior to enrollment: myocardial infarction, stroke or symptomatic peripheral vascular disease
+History of any one or more of the following conditions within 6 months of registration:\r\n* Cardiac angioplasty or stenting\r\n* Myocardial infarction\r\n* Unstable angina\r\n* Coronary artery bypass graft surgery\r\n* Symptomatic peripheral vascular disease\r\n* Pneumonitis
+History of any one or more of the following cardiovascular conditions within the past 6 months:\r\n* Cardiac angioplasty or stenting\r\n* Myocardial infarction\r\n* Unstable angina\r\n* Coronary artery bypass graft surgery\r\n* Symptomatic peripheral vascular disease
+History of myocardial infarction or unstable angina within 6 months prior to day 1
+History of myocardial infarction or unstable angina within 6 months prior to day -3
+History of documented myocardial infarction or cerebrovascular accident
+History of myocardial infarction within 6 months of enrollment
+History of any one or more of the following cardiovascular conditions within the past 6 months:\r\n* Angioplasty or stenting\r\n* Myocardial infarction\r\n* Unstable angina\r\n* Coronary artery by-pass graft surgery\r\n* Symptomatic peripheral vascular disease
+Patients with myocardial infarction or unstable angina =< 6 months prior to starting study drug
+Myocardial infarction within 12 months prior to starting study
+History of myocardial infarction, unstable angina, stroke, or transient ischemic attack within 12 months prior to day 1
+Myocardial infarction within four months prior to enrollment
+Myocardial infarction within 6 months of treatment
+Patients with myocardial infarction or unstable angina =< 6 months prior to registration
+Patients with clinically significant cardiovascular disease: history of cerebrovascular accident (CVA) within 6 months, myocardial infarction or unstable angina within 6 months, or unstable angina pectoris
+History of myocardial infarction or unstable angina within 12 months prior to day 1
+History of myocardial infarction within 6 months prior to day 1
+Known myocardial infarction, severe/unstable angina, percutaneous transluminal coronary angioplasty/stenting (PTCA), or coronary artery bypass graft (CABG) within 6 month of the first dose of the study treatment
+Acute myocardial infarction ?6 months prior to study participation
+Patients who have the following risk factors are considered to be at increased risk for cardiac toxicities; these patients should have increased monitoring:\r\n* Prior treatment with anthracyclines\r\n* Prior treatment with trastuzumab\r\n* A New York Heart Association classification of II controlled with treatment\r\n* Prior central thoracic radiation therapy (RT), including RT to the heart\r\n* History of myocardial infarction within 12 months (patients with history of myocardial infarction within 6 months are excluded from the study)
+Myocardial infarction within 3 months prior to starting treatment
+No evidence of congestive heart failure, symptoms of coronary artery disease, myocardial infarction less than 6 months prior to entry, serious cardiac arrhythmias, or unstable angina; patients who are over 40 or have had previous myocardial infarction greater than 6 months prior to entry will be required to have a negative or low probability cardiac stress test for cardiac ischemia
+Subject has history of severe/unstable angina, myocardial infarction or cerebrovascular accident within 6 months prior to the planned first dose of study drug.
+Unstable angina pectoris or myocardial infarction less than 6 months prior to starting either study drug
+History of myocardial infarction or unstable angina within 6 months prior to enrollment.
+Patients with a history of known coronary artery disease or a myocardial infarction within the last 12 months
+Subject has history of severe/unstable angina, myocardial infarction or cerebrovascular accident within 6 months prior to the planned first dose of study drug.
+Subject has history of severe/unstable angina, myocardial infarction or cerebrovascular accident within 6 months prior to the first dose of study drug.
+Unstable angina (angina symptoms at rest), new-onset angina (begun within the last 3 months). Myocardial infarction less than 6 months before start of study treatment
+Myocardial infarction or uncontrolled angina within 3 months;
+Echocardiogram should be done within 7 days of starting therapy if there are cardiac risk factors (e.g., history of hypertension or of myocardial infarction)
+History of stroke, unstable angina, myocardial infarction, or ventricular arrhythmia requiring medication or mechanical control within the last 6 months
+Acute myocardial infarction (AMI) or unstable angina pectoris < 3 months prior to study entry
+Patients with a history of myocardial infarction that is < 3 months prior to registration
+Myocardial infarction in the previous 12 weeks (from the start of treatment)
+Documented myocardial infarction or unstable/uncontrolled cardiac disease within 6 months of enrollment
+History of myocardial infarction or unstable angina within 6 months prior to Day 1
+Myocardial infarction within the past 6 months, unstable and/or symptomatic arrhythmia, or evidence of ischemia on ECG.
+Any history of major myocardial infarction, stroke or transient ischemic attack (TIA); minor acute myocardial infarction (AMI) and patients who have had cardiac bypass free of symptoms for at least 2 years may be eligible at the discretion of the study chair
+History of myocardial infarction or stroke within the last 6 months, or history of uncontrolled cardiovascular or cerebrovascular disease; a 12-lead electrocardiogram (ECG) will be performed during the screening period
+History of myocardial infarction within 6 months
+Hemodynamically unstable patients (not in cardiogenic shock or having an acute myocardial infarction [MI])
+Active coronary artery disease, unstable or newly diagnosed angina or myocardial infarction less than 6 months prior to first study drug administration
+Has a medical history of myocardial infarction or unstable angina.
+History of myocardial infarction or unstable angina within 6 months prior to first study treatment
+unstable angina or myocardial infarction within 6 months of enrollment.
+Past history of myocardial infarction in the prior 12 months
+Unstable angina pectoris or myocardial infarction ? 6 months prior to starting CC
+Patients with myocardial infarction or unstable angina =< 6 months prior to starting study drug
+Acute myocardial infarction or angina pectoris ? 6 months prior to starting study drug
+Myocardial infarction ? 6 months prior to enrolment.
+History of a stroke or transient ischemic attack, unstable angina, myocardial infarction, or cardiac symptoms within 6 months prior to the first dose of treatment.
+History of myocardial infarction within 6 months prior to the first dose of study-drug treatment in Cycle 1
+Myocardial infarction, unstable angina, coronary artery bypass graft, coronary artery angioplasty or stent placement within 12 months before scheduled dosing day 1;
+Recent history of myocardial infarction (MI) or symptomatic coronary artery disease within the preceding 6 months
+Thromboembolic events, stroke, or ST-elevated myocardial infarction within 7 days of surgery.
+Patients with myocardial infarction or unstable angina ? 6 months prior to starting study drug.
+Myocardial infarction <6 months from study entry
+Myocardial infarction or unstable angina < 6 months prior to enrollment
+History of unstable angina or myocardial infarction within 12 months prior to Day 1 or ischemic heart disease.
+History of myocardial infarction within the last 6 months
+Active coronary artery disease, defined as myocardial infarction, unstable angina, coronary bypass graft, or stenting within 6 months prior to study entry
+A history of acute coronary syndromes (including myocardial infarction or unstable angina), coronary angioplasty, or stenting within 6 months prior to randomization
+History of acute coronary syndromes (including myocardial infarction, unstable angina, coronary artery bypass grafting [CABG], coronary angioplasty, or stenting) < 6 months prior to screening
+Myocardial infarction within 6 months prior to screening;
+A history of acute coronary syndromes (including myocardial infarction or unstable angina), coronary angioplasty, or stenting within 6 months prior to randomization
+Myocardial infarction, severe angina, or unstable angina within 6 months prior to administration of first dose of study drug
+Recent acute coronary syndrome (ACS)/acute myocardial infarction (AMI) – defined as within 24 weeks prior to screening
+Myocardial infarction within 6 months of cycle 1 day 1 (C1D1); subjects with a history of myocardial infarction between 6 and 12 months prior to C1D1 who are asymptomatic and have had a negative cardiac risk assessment (treadmill stress test, nuclear medicine stress test, or stress echocardiogram) since the event may participate
+History of myocardial infarction within 6 months prior to Cycle 1, Day 1, or history of unstable angina
+Myocardial infarction (MI) within 6 months prior to first study drug administration
+History of myocardial infarction or cerebrovascular accident within 6 months of enrollment date.
+History of myocardial infarction or unstable angina within 6 months of enrollment
+Unstable angina or myocardial infarction within 6 months prior to first dose
+Acute myocardial infarction ? 3 months prior to starting study drug
+A history (within 6 months prior to first dose of study treatment) of acute coronary syndromes (including myocardial infarction or unstable angina), coronary angioplasty
+History of myocardial infarction, acute inflammatory heart disease, unstable angina, or uncontrolled arrhythmia within the past 6 months.
+Myocardial infarction (MI) within 6 months prior to first study drug administration
+Thromboembolic or myocardial infarction event within 6 months
+Myocardial infarction within 6 months of Screening visit;
+Have active angina pectoris, stroke or recent myocardial infarction (within 6 months).
+History of myocardial infarction, severe or unstable angina, peripheral vascular disease or familial QTc prolongation.
+Transmural myocardial infarction or unstable angina within 3 months prior to study registration
+History of myocardial infarction within 6 months of Cycle 1, Day 1
+History of myocardial infarction within 6 months prior to screening
+History of myocardial infarction or uncontrolled angina within 12 months prior to administration of study drug
+Myocardial infarction or unstable angina within 6 months prior to the first administration of study drug;
+Unstable angina or myocardial infarction within 6 months of enrolment,
+Acute myocardial infarction or angina pectoris ? 3 months prior to starting study drug
+History of myocardial infarction within 6 months before Cycle 1, Day 1, or history of unstable angina
+CHF, symptomatic ischemia, conduction abnormalities uncontrolled by conventional intervention, myocardial infarction within 6m
+CHF, symptomatic ischemia, conduction abnormalities uncontrolled by conventional intervention, and myocardial infarction within 6m
+Myocardial infarction or unstable angina within 6 months of day 1 prior to registration
+Subject has had an acute myocardial infarction (AMI)
+Significant cardiovascular diseases (i.e., hypertension not controlled by medical therapy, unstable angina, history of myocardial infarction within the past 6 months,
+History of a stroke, myocardial infarction, or unstable angina in the previous 6 months
+Myocardial infarction within one year prior to study entry.
+Cardiomyopathy or a myocardial infarction within the past 8 months.
+Significant cardiovascular disease, such as cardiac disease, myocardial infarction within the previous 3 months, unstable arrhythmias, or unstable angina
+Subject has history of severe/unstable angina, myocardial infarction, or cerebrovascular accident within 6 months prior to the first dose of study drug.
+Myocardial infarction (MI) within the prior 3 months
+History of myocardial infarction or unstable angina within 6 months prior to day 1
+History of myocardial infarction within 6 months prior to first dose of study drug
+Any history of myocardial infarction in the past 12 months
+A myocardial infarction within 6 months prior to study entry;
+No unstable angina, myocardial infarction, or coronary angioplasty within the past 3 months or an untreated cardiac dysrhythmia
+Myocardial infarction or unstable angina within 6 or 1 month of starting nintedanib treatment, respectively
+Myocardial infarction, acute coronary syndrome, revascularization surgery, or stroke within 3 months
+Patients with documented myocardial infarction within six months of protocol entry
+Myocardial infarction 6 months prior to screening
+Acute myocardial infarction within 6 months before starting study drug.
+Transmural myocardial infarction within the last 6 months prior to registration
+Active myocardial ischemia (acute ST elevation or non ST elevation myocardial infarction [MI])
+History of unstable angina or myocardial infarction in the last week
+Patients with history of acute myocardial infarction (MI) or cerebrovascular accident (CVA) within the last 12 months
+Acute coronary (e.g. myocardial infarction) or vascular event within the last year as well as uncontrolled coronary heart disease (e.g. progressive angina)
+Patients with a history of myocardial infarction or ischemic heart disease within the past six months
+History of unstable angina or myocardial infarction 1 month prior to study enrollment
+History of myocardial infarction or unstable angina within 12 months prior to day 1
+Myocardial Infarction (MI) within 3 months
+History of coronary artery disease (angina or myocardial infarction)
+History of myocardial infarction or ischemic heart disease within the past six months
+No unstable angina, regular use of nitroglycerin for exertional angina, or myocardial infarction (MI) within the last 12 months
+Patients with a history of myocardial infarction or ischemic heart disease within the past six months
+Unstable cardiac disease or myocardial infarction within 6 months prior to study entry
+Recent myocardial infarction
+History of uncontrolled angina pectoris or myocardial infarction within 6 months prior to Screening;
+No clinical history of acute myocardial infarction within six months of registration
+History of an ischemic cardiac event including myocardial infarction within 3 months of study entry
+Unstable cardiac disease or myocardial infarction within 6 months prior to study entry
+History of unstable angina or myocardial infarction 1 month prior to study enrollment
+History of unstable angina or myocardial infarction 1 month prior to study enrollment
+myocardial infarction (within the last 3 months)
+Patients with myocardial infarction or unstable angina < 6 months prior to starting study
+Medically eligible to use nicotine replacement therapy (patient currently hospitalized with acute myocardial infarction/ST elevation myocardial infarction [STEMI], unstable angina, uncontrolled arrhythmia, stroke, peripheral arterial disease vascular surgery will not be eligible for inclusion)
+History of coronary heart disease (history of myocardial infarction or symptoms of angina), diabetes, stroke, orthopedic conditions which limit mobility
+Myocardial infarction (MI) in the last 6 months
+Myocardial infarction
+Subjects with a history of stroke, unstable angina, myocardial infarction, or ventricular arrhythmia requiring medication or mechanical control
+Subjects with a history of stroke, unstable angina, myocardial infarction, or ventricular arrhythmia requiring medication or mechanical control
+Hospitalization in the past 2 months for any cardiovascular disease, including but not limited to:\r\n* Angina\r\n* Myocardial infarction\r\n* Peripheral vascular disease\r\n* Stroke
+Recent myocardial infarction
+History of myocardial infarction within 6 months of the enrollment
+Significant cardiovascular risk including, but not limited to, recent (within 28 days) coronary stenting or myocardial infarction within 6 months
+Acute myocardial infarction within 28 days
+Previous history of angina pectoris or acute myocardial infarction (MI) within 6 months
+Has history of myocardial infarction within the past 6 months
+Subjects must not have a history of myocardial infarction within 6 months or a history of arterial thromboembolic event within 3 months of the first dose of investigational agent.
+Myocardial infarction within 3 months prior to C1D1.
+Severe uncontrolled cardiac disease within 6 months of study entry, including but not limited to uncontrolled hypertension; unstable angina; myocardial infarction (MI) or cerebrovascular accident (CVA).
+Patients with a history of myocardial infarction are eligible if the event occurred > 6 months prior to entry
+History of prior myocardial infarction or arrhythmia
+History or clinical signs of myocardial infarction within 1 year of study entry
+The patient has had a myocardial infarction in the previous 12 weeks. (Prior to study entry, electrocardiogram [ECG] abnormalities at screening must be documented by the investigator as not medically relevant.)
+Unstable angina, myocardial infarction, known or suspected transient ischemic events, or stroke within 24 weeks of start of Screening.
+History of thrombotic or hemorrhagic stroke or myocardial infarction within 6 months
+Acute myocardial infarction within 6 months before starting study drug.
+Myocardial infarction within the last 6 months
+Severe/unstable angina, coronary artery/peripheral bypass graft, or myocardial infarction.
+Myocardial infarction within the last 6 months